The pharmaceutical company confirmed on Monday that the new delivery system will house four weekly injections within one device. Despite the shift in hardware, Eli Lilly stated that the medication will remain available at the same self-pay price point. The 2.5-milligram starter dose is set at $299 per month when accessed through LillyDirect, the company’s specialized direct-to-consumer digital pharmacy.

Clinical Efficacy and Market Reach

Zepbound is currently approved for chronic weight management in adults with obesity, as well as those who are overweight with at least one related health condition. The treatment’s clinical utility also extends to the management of moderate-to-severe obstructive sleep apnea in obese patients. The label expansion comes as the company seeks to improve patient convenience in an increasingly competitive metabolic health market.

Lilly attributes the surge in demand to the drug's significant clinical outcomes. According to company reports, trial participants receiving a 15-milligram dose lost an average of 20.9% of their body weight over a 72-week period. These results significantly outperformed the placebo group, which saw a weight reduction of only 3.1% during the same timeframe.